Vanguard Global Advisers’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$400K Buy
63,240
+34,366
+119% +$205K ﹤0.01% 2192
2026
Q2
$157K Hold
28,874
– – ﹤0.01% 2597
2026
Q1
$88.6K Buy
+28,874
New +$88.5K ﹤0.01% 2771

Other funds holding STLN

Vanguard Global Advisers's STLN Position: Q3 2026 in Review

Vanguard Global Advisers increased its Starling Oncology (STLN) stake by 119% in Q3 2026, buying an estimated $205K and bringing the position to 63,240 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Vanguard Global Advisers first reported a position in STLN in Q1 2026 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • Vanguard Global Advisers held 63,240 shares of Starling Oncology worth $400K as of Q3 2026.
  • Vanguard Global Advisers bought 34,366 Starling Oncology shares in Q3 2026, an estimated $205K.
  • Starling Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2192 holding.
  • Vanguard Global Advisers first reported a position in Starling Oncology in Q1 2026 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.